跳至主要内容
临床试验/NCT04243057
NCT04243057Unknown不适用

Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study

Beijing Tsinghua Chang Gung Hospital1 个研究点 分布在 1 个国家目标入组 5,000 人开始时间: 2019年8月30日最近更新:
适应症

试验速览

阶段
不适用
入组人数
5,000
试验地点
1
主要终点
RFSR

研究概览

简要总结

This is a multicenter, two-way, non-intervention study. the main purpose: Understand the current status of diagnosis and treatment of cholangiocarcinoma patients in China and observe the effect of different treatment options on patient recurrence and long-term survival

Secondary purpose:

  1. Exploring the actual clinical treatment situation and its compliance with the existing diagnosis and treatment of bile duct cancer
  2. Exploring the establishment of clinical research standard fields and standards for diagnosis and treatment of bile duct cancer

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • above the age of 18 years old, male or female
  • clinical diagnosis of patients with cholangiocarcinoma
  • Child-Pugh classification of A, B
  • Eastern Cooperative Oncology Group scoring system (ECOG) score of 0-2 points

排除标准

  • 未提供

结局指标

主要结局

RFSR

时间窗: 3 years

RFSR-Recurrence Free Survival Rate

次要结局

  • OS(3 years)
  • RFS(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dong Jiahong

Executive President of Beijing Tsinghua Changgung Hospital

Beijing Tsinghua Chang Gung Hospital

研究点 (1)

Loading locations...

相似试验